ISRG Intuitive Surgical, Inc.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.…
Industry Peers
Medical Instruments & SuppliesKey Statistics
About Intuitive Surgical (NASDAQ: ISRG)
›
Intuitive Surgical (NASDAQ: ISRG) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Instruments & Supplies industry, part of the Healthcare sector, and reports about 17,021 employees.
The shares were at 399.05 USD on 20 November 2026, down 28.7% over 52 weeks. Its 52-week range is 328.57 USD to 603.88 USD: the price is 33.9% below the high and 21.5% above the low.
At a market capitalisation of 138.33B USD, it trades at 48.3 times trailing earnings and 32.0 times forward earnings. The median trailing P/E of its 18 largest Medical Instruments & Supplies peers is 50.2, so ISRG is valued in line with them.
Intuitive Surgical reports return on equity of 16.0%, an operating margin of 31.7% and revenue up 21.7% year over year.
It holds more cash than debt, a net cash position of 4.04B USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 30 analysts cover the stock, with an average rating of Buy; their mean price target of 488.53 USD is 22.4% above the current price. The next earnings report is expected on 21 January 2027.